Agenus (AGEN) Expected to Announce Earnings on Monday

Key Points

• Agenus (NASDAQ:AGEN) is expected to report Q1 2026 results before the open on Monday, May 11, with analysts forecasting EPS $1.95 and revenue $129.5M; an earnings call is scheduled for Tuesday, May 12 at 4:00 PM ET.
• In its last report (Mar. 16) Agenus posted $0.56 EPS and $34.2M in revenue, beating estimates; analysts now expect about $1 EPS for the current fiscal year and -$2 EPS for the next.
• Shares traded around $3.86 (up 0.6%) with a market cap near $148.4M; the consensus rating is "Moderate Buy" and the consensus price target is $14.50, with roughly 61% institutional ownership.

Agenus (NASDAQ:AGEN - Get Free Report) is anticipated to post its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect Agenus to post earnings of $1.95 per share and revenue of $129.50 million for the quarter. Individuals may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:00 PM ET.

Agenus (NASDAQ:AGEN - Get Free Report) last announced its quarterly earnings results on Monday, March 16th. The biotechnology company reported $0.56 earnings per share for the quarter, beating the consensus estimate of ($1.27) by $1.83. Agenus had a negative net margin of 2.67% and a negative return on equity of 7.65%. The business had revenue of $34.20 million during the quarter, compared to analysts' expectations of $28.10 million. On average, analysts expect Agenus to post $1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Agenus Trading Up 0.6%

Shares of AGEN stock traded up $0.02 during mid-day trading on Monday, reaching $3.86. The stock had a trading volume of 181,178 shares, compared to its average volume of 749,271. The firm has a market capitalization of $148.37 million, a PE ratio of -8.38 and a beta of 1.60. The stock's 50-day moving average price is $3.66 and its two-hundred day moving average price is $3.68. Agenus has a 52-week low of $2.71 and a 52-week high of $7.34.

Analysts Set New Price Targets

A number of research firms have commented on AGEN. Zacks Research raised Agenus from a "hold" rating to a "strong-buy" rating in a research report on Thursday, April 2nd. Wall Street Zen upgraded Agenus from a "hold" rating to a "buy" rating in a research report on Monday, April 6th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $14.50.

Institutional Trading of Agenus

Institutional investors and hedge funds have recently bought and sold shares of the stock. LPL Financial LLC boosted its position in Agenus by 20.3% during the 4th quarter. LPL Financial LLC now owns 23,326 shares of the biotechnology company's stock valued at $73,000 after acquiring an additional 3,943 shares in the last quarter. EP Wealth Advisors LLC bought a new position in shares of Agenus in the 4th quarter worth approximately $31,000. Jump Financial LLC purchased a new position in shares of Agenus in the 2nd quarter valued at approximately $55,000. Squarepoint Ops LLC purchased a new position in shares of Agenus in the 3rd quarter valued at approximately $54,000. Finally, Tower Research Capital LLC TRC boosted its position in shares of Agenus by 265.9% during the second quarter. Tower Research Capital LLC TRC now owns 21,871 shares of the biotechnology company's stock valued at $100,000 after purchasing an additional 15,893 shares in the last quarter. 61.46% of the stock is currently owned by hedge funds and other institutional investors.

Agenus Company Profile

Agenus, Inc NASDAQ: AGEN is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system's response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus' pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.